JW (Cayman) Therapeutics Co (HKSE:02126) Change In Receivables : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Change In Receivables?

JW (Cayman) Therapeutics Co's change in receivables for the quarter that ended in Dec. 2023 was HK$0.0 Mil. It means JW (Cayman) Therapeutics Co's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

JW (Cayman) Therapeutics Co's change in receivables for the fiscal year that ended in Dec. 2023 was HK$5.8 Mil. It means JW (Cayman) Therapeutics Co's Accounts Receivable declined by HK$5.8 Mil from Dec. 2022 to Dec. 2023 .

JW (Cayman) Therapeutics Co's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. JW (Cayman) Therapeutics Co's liquidation value for the six months ended in Dec. 2023 was HK$613.7 Mil.

JW (Cayman) Therapeutics Co Change In Receivables Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Change In Receivables Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-5.92

5.80

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial						-	-	-	-	-

JW (Cayman) Therapeutics Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

JW (Cayman) Therapeutics Co (HKSE:02126) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

JW (Cayman) Therapeutics Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, JW (Cayman) Therapeutics Co's accounts receivable are only considered to be worth 75% of book value:

JW (Cayman) Therapeutics Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1100.242	-	505.609	+	0.75 * 0	+	0.5 * 38.039
=	613.7

JW (Cayman) Therapeutics Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines